Tyler Zeronda

CIK: 0001867033

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)9 (75.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

YARW

Yarrow Bioscience, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

YARW
Yarrow Bioscience, Inc.
Oct 29, 2026
Award(A)
Stock Option (Right to Buy)
Direct
156.1K shares-
YARW
Yarrow Bioscience, Inc.
Jul 27, 2026
Award(A)
Stock Option (Right to Buy)
Direct
185.8K shares-
VYNE
VYNE Therapeutics Inc.
Jul 23, 2026
Tax Payment(F)
Direct
22.5K shares at avg. $0.90$20K
VYNE
VYNE Therapeutics Inc.
Jun 30, 2026
Tax Payment(F)
Direct
3.5K shares at avg. $0.65$2K
VYNE
VYNE Therapeutics Inc.
Mar 31, 2026
Tax Payment(F)
Direct
4K shares at avg. $0.60$2K
VYNE
VYNE Therapeutics Inc.
Dec 31, 2025
Tax Payment(F)
Direct
7.9K shares at avg. $0.58$5K
VYNE
VYNE Therapeutics Inc.
Sep 30, 2025
Tax Payment(F)
Direct
3.4K shares at avg. $0.34$1K
VYNE
VYNE Therapeutics Inc.
Jun 30, 2025
Tax Payment(F)
Direct
3.4K shares at avg. $1.65$6K
VYNE
VYNE Therapeutics Inc.
Mar 31, 2025
Tax Payment(F)
Direct
8.4K shares at avg. $1.58$13K
VYNE
VYNE Therapeutics Inc.
Jan 21, 2025
Award(A)
Stock Option (right to buy)
Direct
230K shares-
VYNE
VYNE Therapeutics Inc.
Dec 31, 2024
Tax Payment(F)
Direct
4.7K shares at avg. $3.35$16K
VYNE
VYNE Therapeutics Inc.
Sep 30, 2024
Tax Payment(F)
Direct
84 shares at avg. $1.88$157.92

		Type	Shares	Price		Ownership
Oct 29, 2026	YARW Yarrow Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	156,115	-	-	Direct
Jul 27, 2026	YARW Yarrow Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	185,798	-	-	Direct
Jul 23, 2026	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	22,516	$0.90	$20,210	Direct
Jun 30, 2026	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	3,464	$0.65	$2,254	Direct
Mar 31, 2026	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	4,007	$0.60	$2,394	Direct
Dec 31, 2025	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	7,858	$0.58	$4,558	Direct
Sep 30, 2025	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	3,420	$0.34	$1,146	Direct
Jun 30, 2025	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	3,420	$1.65	$5,643	Direct
Mar 31, 2025	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	8,399	$1.58	$13,270	Direct
Jan 21, 2025	VYNE VYNE Therapeutics Inc.	Award(A) Stock Option (right to buy)	230,000	-	-	Direct
Dec 31, 2024	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	4,675	$3.35	$15,661	Direct
Sep 30, 2024	VYNE VYNE Therapeutics Inc.	Tax Payment(F)	84	$1.88	$158	Direct

1-12 of 12 transactions

About Zeronda Tyler

Zeronda Tyler (SEC CIK 0001867033) files insider reports with the SEC as Chief Financial Officer of Yarrow Bioscience, Inc. (YARW).

Signal8 holds 12 ownership filings by Zeronda Tyler, all Form 4s, filed between Oct 2, 2024 and Oct 30, 2026. Those filings report 12 transactions, from Sep 30, 2024 to Oct 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zeronda Tyler's filings is in NEW HAVEN, CT.

Recent filings by Zeronda Tyler

Oct 29, 2026: Grant or award of YARW derivative securities (Form 4, code A).
Jul 27, 2026: Grant or award of YARW derivative securities (Form 4, code A).
Jul 23, 2026: Tax withholding of VYNE shares (Form 4, code F).
Jun 30, 2026: Tax withholding of VYNE shares (Form 4, code F).
Mar 31, 2026: Tax withholding of VYNE shares (Form 4, code F).

Other insiders filing for Yarrow Bioscience, Inc. (YARW)

Payton Lori, Chief Development Officer
Alford Rachael, Chief Operating Officer
Frey Rebecca, Chief Executive Officer
Ryder Steven, Chief Medical Officer
RTW Fund Group GP, LLC, 10% Owner
Ashiya Mona, Director

How to read Form 4 transaction codes